Skip to content

PolitiKit

Lobbying by Pfizer Canada ULC: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Corporation

Pfizer Canada ULC

Meetings this Parliament
35
With MPs
12
Since Nov 2021
114
Active registrations
1

Most recent reported meeting: Aug 6, 2026.

Registrations in effect

In-house (corporation) In effect since Jul 13, 2026

Filed by An Van Gerven, President

Lobbyists

  • An Van Gerven · President
  • Steven Hogue · Director, Global Policy and Public Affairs (Canada) Former public office holder

    Formerly Deputy Director of Communications, Communications, Office of the Prime Minister of Canada (2002–2003)

    Formerly Special Assistant (Quebec Issues), Operations, Office of the Prime Minister of Canada (2001–2002)

    Formerly Special Assistant (Quebec and Atlantic Issues), Minister's Office, Department of Fisheries & Oceans (1999–2001)

    Formerly Special Assistant (Quebec and Atlantic Issues), Minister's Office, Canada Customs and Revenue Agency (1998–1999)

Institutions they may lobby: Atlantic Canada Opportunities Agency (ACOA), Canada Border Services Agency (CBSA), Canada Economic Development for Quebec Regions, Canada Revenue Agency (CRA), Canadian Institutes of Health Research (CIHR), Employment and Social Development Canada (ESDC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Justice Canada (JC), National Defence (DND), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)

What they're lobbying on (22)
  • Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB).
  • Free trade agreements as they relate to the biopharmaceutical industry.
  • Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.
  • Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.
  • Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals.
  • Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policy
  • Monitoring and engaging on the Government’s national strategy for rare diseases; the Canadian Drug Agency; and the implementation of C64, An Act to Implement pharmacare.
  • Patented Medicine Prices Review Board (PMPRB) amendments to the Patented Medicines Regulations and the related new guidelines.
  • Advocacy on the Regulations Amending the Patent Rules and Certain Regulations Made Under the Patent Act which were published for consultation in Canada Gazette Part I (CGI) on May 18, 2024.1 Share concerns with Canada’s implementation of a patent term adjustment (PTA) system that is not compliant with its trade obligations, as it does not provide a meaningful remedy to patentees who are impacted by unreasonable patent office delays.
  • Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement
  • Advocacy on the role of the Health Emergency Readiness Canada (HERC) Agency
  • Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods
  • The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.
  • Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Drug Agency as well as the review times and processes conducted by Health Canada for the purpose of obtaining a notice of compliance.
  • Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy
  • Health Canada’s policies, program and guidelines related to the management, prevention, mitigation and notification of drug shortages
  • Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries
  • Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.
  • Discussions on the procurement of a COVID19 vaccine and therapy
  • Discussions around the World Trade Organization consideration of a TRIPS Patent Waiver and the World Health Organization pandemic treaty proposal
  • Consider amendments to the Food and Drugs Act, or the Export and Imports Permits Act (Export Control List) or any other legislative and regulatory means in order to protect the Canadian supply of drugs in light of potential importation legislation in the United States.
  • Advocacy to maintain and increase funding for the National Immunization Strategy and discussions on vaccine procurement.

Registration 960525-15283-47. Look it up in the official Registry

Reported meetings

Spreadsheet

Filed by Najah Sampson (55), An Van Gerven (36), Cole C. Pinnow (23).

  • Reported by An Van Gerven · In-house (corporation)

    • Janice Charette · Chief Trade Negotiator, Global Affairs Canada (GAC)
    Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals. Read more

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Mark Wiseman · Ambassador of Canada to the United States, Global Affairs Canada (GAC)
    Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policy Read more

    Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals.

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Julie Harb · Policy Advisor, Prime Minister's Office (PMO)
    Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policy Read more

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.

    Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals.

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Martin Moen · Associate Asst Dep. Minister of International Trade and Chair of the Canada/U.S. Trade and Economic Task Force, Global Affairs Canada (GAC)
    Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Marjorie Michel · Ministre de la Sante, Health Canada (HC)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    • Kaili Levesque · Associate Deputy Minister, Fisheries and Oceans Canada (DFO)
    and 10 more
    • Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
    • Elizabeth Wong · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Annahat Kochhar · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Fatouma Bah · Policy Advisor, Health Canada (HC)
    • Supriya Sharma · Acting ADM, Health, Health Canada (HC)
    • Scott Lohnes · Senior Advisor, Health Canada (HC)
    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations. Read more

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Mélanie Joly · Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, Innovation, Science and Economic Development Canada (ISED)
    Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policy Read more

    Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement

    Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals.

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Kaili Levesque · Associate Deputy Minister, Fisheries and Oceans Canada (DFO)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    • Elizabeth Wong · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    and 6 more
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    • Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations. Read more

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Kaili Levesque · Associate Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    and 6 more
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Jibril Hussein · Senior Policy Advisor, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    • Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations. Read more

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Arianne Reza · Associate Deputy Minister, Public Services and Procurement Canada (PSPC)
    • Joelle Paquette · Associate Assistant Deputy Minister, Public Services and Procurement Canada (PSPC)
    Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals. Read more

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy Read more

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Tim Krupa · Director of Policy, Prime Minister's Office (PMO)
    • Brandan Rowe · Chief of Staff, Privy Council Office (PCO)
    • Martin Moen · Associate Asst Dep. Minister of International Trade and Chair of the Canada/U.S. Trade and Economic Task Force, Global Affairs Canada (GAC)
    Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement Read more

    Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals.

    Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policy

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
    and 3 more
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations. Read more

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals. Read more

    Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policy

    Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods

    Free trade agreements as they relate to the biopharmaceutical industry.

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Maggie Chi · Member of Parliament
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Elizabeth Wong · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Annahat Kochar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    and 7 more
    • Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policy Read more

    Free trade agreements as they relate to the biopharmaceutical industry.

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.

    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Marjorie Michel · Ministre de la Sante, Health Canada (HC)
    • Sony Perron · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    and 5 more
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Deputy Chief of Staff & Director of Policy, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
    Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policy Read more

    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.

    Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB).

    Free trade agreements as they relate to the biopharmaceutical industry.

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
    • Karim Bardeesy · Member of Parliament
    • Marjorie Michel · Ministre de la Sante, Health Canada (HC)
    • Janice Charette · Chief Trade Negotiator, Global Affairs Canada (GAC)
    and 7 more
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
    • Martin Moen · Associate Assistant Deputy Minister of the International Trade Branch, Global Affairs Canada (GAC)
    • Justine Frame · Special Assistant - Policy, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Sharlene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    Consider amendments to the Food and Drugs Act, or the Export and Imports Permits Act (Export Control List) or any other legislative and regulatory means in order to protect the Canadian supply of drugs in light of potential importation legislation in the United States. Read more

    Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policy

    Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement

    Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.

    The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.

    Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy

    Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals.

    Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Kabisan Thanendran · Policy Advisor, Public Services and Procurement Canada (PSPC)
    • Chanel Sterie · Senior Policy Advisor, Public Services and Procurement Canada (PSPC)
    Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals. Read more

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Paul Moen · Chief of Staff to the Minister, Innovation, Science and Economic Development Canada (ISED)
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policy Read more

    Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals.

    Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement

    Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.

    The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.

    Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policy Read more

    The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy Read more

    Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policy

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Ritu Banerjee · Associate Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement Read more

    Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.

    Advocacy on the role of the Health Emergency Readiness Canada (HERC) Agency

    Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods

    Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy

    The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Paul Hebert · President, Canadian Institutes of Health Research (CIHR)
    Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy. Read more

    The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.

    Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • Ian Foucher · Chief of Staff to the Minister, Finance Canada (FIN)
    • Matthew O'Connell · Deputy Director of Policy, Office of the Minister, Finance Canada (FIN)
    Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Drug Agency as well as the review times and processes conducted by Health Canada for the purpose of obtaining a notice of compliance. Read more

    Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods

    Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement

    Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.

    The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.

    Official report

  • Reported by An Van Gerven · In-house (corporation)

    • David McFarlane · Director of Policy, Innovation, Science and Economic Development Canada (ISED)
    Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement Read more

    Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods

    Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Drug Agency as well as the review times and processes conducted by Health Canada for the purpose of obtaining a notice of compliance.

    Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.

    The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.